Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis

Trial details

Who runs it

Mayo Clinic

Trial code

NCT06329492

Record updated

12 February 2026

Original description

The purpose of this study is to determine the effectiveness and safety of autologous alpha-2 macroglobulin rich plasma (A2MRP) injections in the treatment of knee osteoarthritis (OA).Read full original descriptionShow less

Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP), Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis: A Pilot Study

The purpose of this study is to determine the effectiveness and safety of autologous alpha-2 macroglobulin rich plasma (A2MRP) injections in the treatment of knee osteoarthritis (OA).

Inclusion: Male or females,18-65 years of age; Chronic (> 3 months), unilaterally symptomatic, primary knee OA; Painful knee OA in one or more knee compartments grade 2-3 radiologic severity based upon the Kellgren-Lawrence grading scale, without evidence of advanced (bone on bone, as determined by study investigators) OA in the patellofemoral compartment or on Posterior Anterior (PA) flexion views; Cognitive ability to give informed consent; Speak fluent English; Worst knee pain greater than 4 on a 0-10 pain scale (0 = no pain, 10 = worst pain imaginable); Previous 6 week or longer trial of one of the following conservative treatments: activity modification, weight loss, physical therapy, anti-inflammatory medications/acetaminophen or injection therapy (e.g., cortisone); Fully understanding of the requirements of the study and willingness to comply with the treatment plan, including blood draw, laboratory tests, diagnostic imaging, and follow-up visits and assessments; Can provide written informed consent and complete HIPAA documentation after the nature of the study is fully explained and prior to any study-related procedure.

Exclusion: Injections of any kind into the target knee:; Corticosteroid injections within 3 months prior to study enrollment; Hyaluronic acid injections within 6 months prior to study enrollment; PRP injection within the year prior to study enrollment; History of BMAC, Micro-Fragmented Adipose Tissue (MFAT), or perinatal product injection at any point; Inability to stop non-steroidal anti-inflammatory medications for 1 week before through 2 weeks after the procedure date; On chronic, immunosuppressive transplant therapy or having a chronic, immunosuppressive state, including use of systemic steroids/corticosteroids; Surgery in the target knee within the last 12 months, or planned surgery in the target knee in next 12 months; History of intra-articular infection in the target knee; History of superficial infection in the target knee within 6 months of study enrollment, or evidence of current superficial infection affecting the target knee; Clinically significant rheumatological or inflammatory disease or chondrocalcinosis/ calcium pyrophosphate disease (CPPD), hemochromatosis, inflammatory arthritis, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, ochronosis, hemophilic arthropathy, systemic sclerosis, system lupus erythematosus, and Ehlers-Danlos Syndrome, infectious arthritis, Charcot's knee joint, villonodular synovitis, and synovial chondromatosis; Pregnant or nursing, or planning on becoming pregnant during the study period; Congenital or acquired malformation of the target knee resulting in significant deformity or leading to problems with the study treatment or analysis of the results; Significant valgus or varus malalignment as determined by investigator; Body mass index (BMI) < 35 kg/m2; Current tobacco product use, including nicotine patch or other nicotine products.

ClinicalTrials.gov NCT06329492